European approval of HIV drug darunavir will provide a potent new option with Fuzeon
Basel (CH), 16 February 2007. Today's conditional marketing authorisation in the European Union of the new protease inhibitor (PI) darunavir (boosted with ritonivir) provides physicians with the opportunity to build a potent new treatment combination with the fusion inhibitor, FUZEON. The combination of FUZEON and boosted darunavir has been shown to give treatment-experienced patients a better c...FUZEON with investigational HIV drug results in remarkable number of patients achieving undetectable
Basel, October 5, 2006 -- Exciting new clinical data demonstrate that 90 to 95 percent of treatment-experienced HIV patients who initiate therapy with FUZEON (enfuvirtide) and the investigational integrase inhibitor MK-0518 can achieve undetectable levels of HIV (less than 400 copies per mL of blood)1. Such response rates have never been achieved in clinical trials of HIV patients living with d...